At ID Week 2022, VA executives presented a poster session titled, highlighting how high-risk patients with mild to moderate disease were identified as a group who would benefit from COVID-19 monoclonal antibody (mAB) treatment to mitigate progression to severe disease or hospitalization.
Read More